Skip to content
OpenCapital
Get started

Citius Oncology, Inc. CTOR Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect

Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect at other companies

KRAKacquisition logo
KRAKacquisition KRAQ
$44.15K—
Rumble, Inc. logo
Rumble, Inc.RUM
-$18.88M-110%
SkyWest logo
SkyWestSKYW
-$56.83M-17.4%
Ondas, Inc. logo
Ondas, Inc. ONDS
$443M+9,754%
Hooker Furnishings Corporation logo
Hooker Furnishings CorporationHOFT
$9.51M-18.9%
Paycom Software logo
Paycom SoftwarePAYC
-$2.73B-65.4%

Other financials

Income statement

See full
Revenue$1.7M—
Gross profit$1.3M—
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-74.7%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect?
Citius Oncology, Inc. (CTOR) reported cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect of -$4.66M in Q1 2026.
How has Citius Oncology, Inc.'s cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect changed year-over-year?
Citius Oncology, Inc.'s cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect decreased by 575.2% year-over-year, from $981.2K to -$4.66M.
What does cash cash equivalents restricted cash and restricted cash equivalents period increase decrease excluding exchange rate effect mean?
Represents the total net change in the company's liquid assets, including cash, cash equivalents, and restricted funds, over a specific period. This metric provides a comprehensive view of the company's overall cash flow health and liquidity position.